In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 6, 1997, Pages 493-497

  Alberts, David S ^a   Fanta, Paul T ^a   Running, Kelli L ^a   Adair Jr , Laurence P ^a   Garcia, Dava J ^a   Liu Stevens, Rosa ^a   Salmon, Sydney E ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Chemotherapy; Nedaplatin; Ovarian cancer; Platinum analog

Indexed keywords

CARBOPLATIN; CISPLATIN; NEDAPLATIN; PLATINUM DERIVATIVE;

ARTICLE; BIOPSY; COLONY FORMING UNIT; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS;

EID: 0031037594     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050604     Document Type: Article

References (23)

1. Alberts DS, Salmon SE, Chen HSG, Moon TE, Young L, Surwit EA (1981) Pharmacologic studies of anticancer drugs with the human tumor stem cell assay. Cancer Chemother Pharmacol 6:253
2. Ariyoshi Y, Ota K, Wakui A, Majima H, Nittani H, Ogawa M, Inuyama Y, Yoshida O, Taguchi T, Kimura I, Kato T (1988) Phase I study of (glycolato-0-0′) diammineplatinum(II) (254-S). Proc Am Soc Clin Oncol 7:222
3. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR (1982) Early clinical studies with cis-diamminedichloroplatinum(II) (cisplatin). Cancer Chemother Pharmacol 9:140
4. Evans BD, Raju KS, Calvert AH, Harland SJ, Wiltshaw E (1983) Phase II study of JM8, a new platinum analog in advanced ovarian cancer. Cancer Treat Rep 67:997
5. Fukuda M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F, Hara K, Saijo N (1990) Phase II study of (glycolato-0-0′) diammineplatinum(II), a novel platinum complex, in the treatment with non-small-cell lung cancer. Cancer Chemother Pharmacol 26:393
6. Goel R, Andrews PA, Pfeifle CE, Abramson S, Kirmani S, Howell SB (1990) Comparison of the pharmacokinetics of ultrafilterable cisplatin species detectable by derivatization of diethyl-dithiocarbamate with atomic absorption spectroscopy. Eur J Cancer 26:21
7. Hamburger AW, Salmon SE, Kim MB, Trent JM, Soehnlen BJ, Alberts DS (1978) Direct cloning of human ovarian carcinoma cells in agar. Cancer Res 38:3438
8. Hamers FPT, Gispen WH, Neijt JP (1991) Neurotoxic side-effects of cisplatin. Eur J Cancer 27:372
9. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S, Ota K (1992) An early phase II clinical study of cis-diammine glycolatoplatinum, 254-S, for head and neck cancers. Jpn J Cancer Chemother 19:863
10. Kelland LR (1993) New platinum antitumor complexes. Crit Rev Oncol Hematol 15:191
11. Leibovitz A, Liu R, Hayes C, Salmon SE (1983) A hypo-osmotic medium to disaggregate tumor cell clumps into viable and clonogenic single cells for the human tumor stem cell clonogenic assay. Int J Cell Cloning 1:478
12. Mangioni C, Bolis G, Pecorelli S, Bragman K, Epis A, Favalli G, Gambino A, Landoni F, Presti M, Terri W (1990) Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst 81:434
13. Muggia FM, Los G (1993) Platinum resistance: laboratory findings and clinical implications. Stem Cells 11:182
14. Ota K, Wakui A, Majima H, Niitani H, Inuyama Y, Ogawa M, Ariyoshi Y, Yoshida O, Taguchi T, Kimura I (1992) Phase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum(II). Jpn J Cancer Chemother 19:855
15. Ozols RF, Young RC (1984) Chemotherapy of ovarian cancer. Semin Oncol 11:251
16. Rosenberg B (1985) Fundamental studies with cisplatin. Cancer 55:2303
17. Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS, Moon TE (1978) Quantitation of differential sensitivity of human-tumor stem cells to anti-cancer drugs. N Engl J Med 298:1321
18. Sasaki Y, Tamura T, Eguchji K, Shinkai T, Fujiwara Y, Fukuda M, Ohe Y, Bungo M, Horichi N, Niimi S (1989) Pharmacokinetics of (glycolato-0,0′)-diammine platinum (II), a new platinum derivative in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 23:243
19. Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamara T, Ohe Y, Kojima A, Saijo N (1991) Phase 1 study and pharmacological analysis of cis-diammine (glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion. Cancer Res 51:1472
20. Sasaki Y, Shinkai T, Eguchi K, Tamura T, Ohe Y, Ohmori T, Saijo N (1991) Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay. Cancer Chemother Pharmacol 27:263
21. Shiratori O, Kasai H, Uchida N, Takeda Y, Totani T, Sato K (1985) Antitumor activity of 254-S, a platinum complex, in rodents. In: Ishigami J (ed) Recent advances in chemotherapy. University of Tokyo Press, Tokyo, p 635
22. Totani T, Aono K, Adachi Y, Komura M, Shiratori O, Sato K (1988) Bidentate hydroxycarboxylic acid platinum(II) complexes with antitumor activity. In: Marino N (ed) Platinum and other metal coordination compounds in cancer chemotherapy. Martinus Nijhoff, Boston, p 744
23. Warmerdam WC van, Rodenhuis S, Telligen O van, Maes RAA, Beijen JH (1994) Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination. Cancer Chemother Pharmacol 35:179